{
    "clinical_study": {
        "@rank": "47101", 
        "arm_group": [
            {
                "arm_group_label": "LY3041658 (IV)", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of LY3041658, administered as a slow IV infusion in escalating dose cohorts."
            }, 
            {
                "arm_group_label": "LY3041658 (SC)", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of LY3041658 administered SC"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety of LY3041658 in healthy\n      participants, including those of Japanese descent. The study will also investigate how the\n      drug is processed and affects key immune cells.  Study participation will last 4 months."
        }, 
        "brief_title": "Safety Study of LY3041658 in Healthy Participants", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) between 18.0 to 32.0 kilogram per square meter (kg/m2).\n\n          -  Absolute neutrophil count at screening should be \u22651.8 and \u22647.2 x 10^3/microliter\n             (uL), inclusive.\n\n          -  A subset of participants (15 planned) must additionally qualify as first-generation\n             Japanese: the participant, the participant's biological parents, and all of the\n             participant's biological grandparents must be of exclusive Japanese descent and have\n             been born in Japan. First-generation Japanese must be at least 20 years of age at the\n             time of initial screening.\n\n        Exclusion Criteria:\n\n        - Have received antibody-based biologic agents (marketed or investigational) within 3\n        months or 5 half lives (t1/2) of the drug (whichever is longer) prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148627", 
            "org_study_id": "15164", 
            "secondary_id": "I7P-MC-DSAA"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY3041658 (SC)", 
                "description": "Administered SC", 
                "intervention_name": "LY3041658 (SC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY3041658 (IV)", 
                "description": "Administered as slow IV infusion", 
                "intervention_name": "LY3041658 (IV)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered as slow IV infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "antibody", 
            "autoimmune"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The Number of Participants with One or More Drug-Related Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to study completion (Day 85)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY3041658", 
                "safety_issue": "No", 
                "time_frame": "Predose through Day 85, at specified timepoints"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of Last Measurable Concentration (tlast)", 
                "safety_issue": "No", 
                "time_frame": "Predose through Day 85, at specified timepoints"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}